根据最新协议条款，生物制药巨头吉利德科学将保留除大中华区以外的全球独家商业化权利。与此同时，该公司承诺将向合作伙伴Galapagos支付相当于净销售额20%至23%的特许权使用费。
这一安排凸显了吉利德科学在全球市场战略布局中的精准定位，同时通过阶梯式分成模式强化了双方的利益共享机制。特许权使用费的具体比例将根据产品在不同区域的销售表现进行动态调整，既保障了研发方的合理收益，也激励商业化团队持续优化市场推广策略。
值得注意的是，大中华区的商业化权利将采用独立运作模式，这反映出该地区在市场规模、监管环境等方面具备的特殊性。双方未来或将通过另行签订区域许可协议的方式，进一步挖掘亚太市场的增长潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.